AI Insight
A study from UCLA Health Jonsson Comprehensive Cancer Center examined the impact of biosimilars, which are lower-cost versions of biologic drugs used to treat cancers like breast cancer and lymphoma. The research found that increasing use of these biosimilar medications is associated with reduced costs for both insurance providers and patients. Biologic drugs are effective cancer treatments but their high prices contribute significantly to the financial burden of cancer care.
Why it matters
The adoption of biosimilars could make cancer treatment more affordable and accessible while maintaining therapeutic effectiveness. This cost reduction may help alleviate the financial toxicity that many cancer patients experience during treatment, potentially improving treatment adherence and outcomes.
Understand the Science
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Source: Cancer biosimilars associated with lower costs for insurers and patients